Abstract:OBJECTIVE:To study the effect of rifampin (RFP) on the metabonomic profile of rat urine and its relationship with traditional toxicity evaluation of blood biochemical indicators and histopathology.METHODS:Thirty-six male Wistar rats were randomly divided into control group, 50 mg/kg RFP group, and 100 mg/kg RFP group, with 12 rats in each group. Rats in each group were given intragastric infusion with a daily dose of 0, 50 mg/kg RFP, and 100 mg/kg RFP for 3, 7, and 14 days, respectively. Then 4 rats in each group were killed on the next day of administration to collect blood samples and liver sample for the determination of blood biochemical indicators and for the pathological analysis of the liver. The urine specimens over 24 hours of each rat were collected before and after each treatment until the rat was killed. 1H nuclear magnetic resonance (1H NMR) spectra of these urine specimens were acquired and subjected to data preprocess and principal component analyses (PCA).RESULTS:The level of serum total bilirubin of the rat administrated with 100 mg/(kg x d) RFP for 7 days was significantly higher than that of control group (P < 0.05). Mild hepatotoxicity to the rat, treated with RFP of higher dosage (100 mg/kg) and longer duration (14 days), was revealed by the traditional histopathological method. The metabonomic spectra of rat urine in different groups differed from each other; a trajectory bias in determination of rat urine by 1H NMR occurred depending on the administration duration. As demonstrated by 1H NMR spectra of urine in rats treated with RFP, the concentration of urinary citrate and 2-oxoglutarate decreased, along with the remarkable increase of the concentrations of urinary taurine and glucose (compared with those of the control group).CONCLUSIONS:Being consistent with the results of traditional toxicity evaluation measurements, metabonomic method is more sensitive. The 1H-NMR metabonomic profile of the rat urine is closely related with the duration of RFP. The hepatic toxicity induced by RFP is related to the reduction of energy metabolism in tricarboxylic acid cycle and the perturbation of glucose and lipid metabolism.

Regulation of hepatobiliary transporters during cholestasis may mediate the phenomenon of adaptation to cholestasis induced by rifampicin in rats

The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.

Tanshinone IIA Alleviate Rifampicin-Induced Cholestasis by Regulating the Expression and Function of Bile Salt Export Pump.

Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury

Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice.

Screening of Biomarkers and Toxicity Mechanisms of Rifampicin-Induced Liver Injury Based on Targeted Bile Acid Metabolomics

Tanshinone ⅡA May Alleviate Rifampin-Induced Cholestasis by Regulating the Expression and Function of NTCP

Efficacy and Safety of Rifampicin in Patients with Persistent Hepatocellular Secretory Failure

Rifampicin Induces Clathrin-Dependent Endocytosis and Ubiquitin–proteasome Degradation of MRP2 Via Oxidative Stress-Activated PKC-ERK/JNK/p38 and PI3K Signaling Pathways in HepG2 Cells

Rifampicin-Induced Hepatic Lipid Accumulation: Association with Up-Regulation of Peroxisome Proliferator-Activated Receptor γ in Mouse Liver

4-Phenylbutyrate protects against rifampin-induced liver injury via regulating MRP2 ubiquitination through inhibiting endoplasmic reticulum stress

Studies on Rifampicin and Isoniazid-induced Hepatotoxicity Using in Vitro Primary Hepatocytes

Investigation of rifampicin-induced hepatotoxicity in rat hepatocytes maintained in gel entrapment culture

Research on characteristics of liver injury induced by rifampicin in mice

[Metabonomic Profile of Urine from Rats Administrated with Different Treatment Period of Rifampin].

Rifampicin Exacerbates Isoniazid-Induced Toxicity in Human but Not in Rat Hepatocytes in Tissue-Like Cultures

Effects and Mechanisms of Rifampin on Hepatotoxicity of Acetaminophen in Mice

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome

Pyrazinamide alleviates rifampin-induced steatohepatitis in mice by regulating the activities of cholesterol-activated 7α-hydroxylase and lipoprotein lipase

Involvement of endoplasmic reticulum stress in rifampicin-induced liver injury

Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs